BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gasparotto D, Sbaraglia M, Rossi S, Baldazzi D, Brenca M, Mondello A, Nardi F, Racanelli D, Cacciatore M, Paolo Dei Tos A, Maestro R. Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors. JCI Insight 2020;5:142560. [PMID: 33048845 DOI: 10.1172/jci.insight.142560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Fiorino E, Merlini A, D’ambrosio L, Cerviere I, Berrino E, Marchiò C, Giraudo L, Basiricò M, Massa A, Donini C, Leuci V, Rotolo R, Galvagno F, Vitali L, Proment A, Ferrone S, Pisacane A, Pignochino Y, Aglietta M, Grignani G, Mesiano G, Sangiolo D. Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST. IJMS 2022;23:10368. [DOI: 10.3390/ijms231810368] [Reference Citation Analysis]
2 Guo S, Zhang L, Li N. ANO1: More Than Just Calcium-Activated Chloride Channel in Cancer. Front Oncol 2022;12:922838. [PMID: 35734591 DOI: 10.3389/fonc.2022.922838] [Reference Citation Analysis]
3 Rizzo A, Pantaleo MA, Astolfi A, Indio V, Nannini M. The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST). Cancers (Basel) 2021;13:705. [PMID: 33572358 DOI: 10.3390/cancers13040705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chew HY, Chan V, Simpson F, Dolcetti R. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit? Cancers (Basel) 2020;12:E3392. [PMID: 33207697 DOI: 10.3390/cancers12113392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]